{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:19:06Z","timestamp":1790720346432,"version":"4.1.0"},"reference-count":64,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T00:00:00Z","timestamp":1601683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005897","name":"Soci\u00e9t\u00e9 Fran\u00e7aise de Dermatologie","doi-asserted-by":"publisher","award":["2020"],"award-info":[{"award-number":["2020"]}],"id":[{"id":"10.13039\/501100005897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Cutaneous T-cell lymphomas (CTCLs) are non-Hodgkin lymphomas that develop primarily in the skin. They account for almost 80% of primary cutaneous lymphomas. Epidermotropic CTCLs (mycosis fungoides (MF) and S\u00e9zary syndrome (SS)) are the most common form of CTCL. The course of the disease ranges from an indolent clinical behavior in early-stage disease to an aggressive evolution in the advanced stages. Advanced-stage disease is defined by the presence of tumors, erythroderma, or significant blood, nodal or visceral involvement. Advanced-stage disease is characterized by frequent disease relapses, refractory disease, a severely impaired quality of life and reduced overall survival. In the last twenty-five years, allogeneic hematopoietic stem cell transplantation (HSCT) has led to prolonged remissions in advanced CTCL, presumably linked to a graft-versus-lymphoma effect and is thus emerging as a potential cure of the disease. However, the high post-transplant relapse rate and severe morbidity and mortality associated with graft-versus-host disease and infections are important issues. Allogeneic HSCT is thus mostly considered in young patients with no comorbidities and an aggressive, advanced-stage CTCL. Allogeneic HSCT gives the best results in patients with a pre-transplant complete remission of the lymphoma. For this reason, one of the challenges is to define the best time to consider allogeneic HSCT in the disease course. Early identification of patients at high risk for progression is important to identify candidates who may benefit from allogeneic HSCT before their disease becomes treatment-refractory. This review describes the role of allogeneic HSCT in CTCL, summarizes the published data and future perspectives in this area.<\/jats:p>","DOI":"10.3390\/cancers12102856","type":"journal-article","created":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T07:22:16Z","timestamp":1601709736000},"page":"2856","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Allogeneic Hematopoietic Stem Cell Transplantation in Cutaneous T-Cell Lymphomas"],"prefix":"10.3390","volume":"12","author":[{"given":"Ma\u00eblle","family":"Dumont","sequence":"first","affiliation":[{"name":"Department of Dermatology, APHP, Saint-Louis Hospital, F-75010 Paris, France"},{"name":"INSERM U976, Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, F-75010 Paris, France"},{"name":"Department of Medicine, Universit\u00e9 de Paris, F-75010 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9gis","family":"Peffault de Latour","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universit\u00e9 de Paris, F-75010 Paris, France"},{"name":"Hematology-Bone Marrow Transplantation, APHP, Saint-Louis Hospital, F-75010 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Ram-Wolff","sequence":"additional","affiliation":[{"name":"Department of Dermatology, APHP, Saint-Louis Hospital, F-75010 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Bagot","sequence":"additional","affiliation":[{"name":"Department of Dermatology, APHP, Saint-Louis Hospital, F-75010 Paris, France"},{"name":"INSERM U976, Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, F-75010 Paris, France"},{"name":"Department of Medicine, Universit\u00e9 de Paris, F-75010 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7828-6211","authenticated-orcid":false,"given":"Ad\u00e8le","family":"de Masson","sequence":"additional","affiliation":[{"name":"Department of Dermatology, APHP, Saint-Louis Hospital, F-75010 Paris, France"},{"name":"INSERM U976, Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, F-75010 Paris, France"},{"name":"Department of Medicine, Universit\u00e9 de Paris, F-75010 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjd.17240","article-title":"British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018","volume":"180","author":"Gilson","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions to the staging and classification of mycosis fungoides and S\u00e9zary syndrome: A proposal of the international society for cutaneous lymphomas (ISCL) and the cutaneous lymphoma task force of the european organization of research and treatment of cancer (EORTC)","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/s\u00e9zary syndrome: Validation of the revised international society for cutaneous lymphomas\/european organisation for research and treatment of cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and s\u00e9zary syndrome: Effect of specific prognostic markers on survival and development of a prognostic model","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.beha.2018.07.007","article-title":"Integrating novel systemic therapies for the treatment of mycosis fungoides and S\u00e9zary syndrome","volume":"31","author":"Prince","year":"2018","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","article-title":"European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome\u2014Update 2017","volume":"77","author":"Trautinger","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbmt.2019.08.019","article-title":"Efficacy of allogeneic hematopoietic cell transplantation in cutaneous T cell lymphoma: Results of a systematic review and meta-analysis","volume":"26","author":"Iqbal","year":"2020","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/sj.bmt.1702099","article-title":"Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: Evidence of a graft-versus-tumor effect","volume":"25","author":"Burt","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/sj.bmt.1704641","article-title":"Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation","volume":"34","author":"Herbert","year":"2004","journal-title":"Bone Marrow Transpl."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1200\/JCO.2010.29.3241","article-title":"Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and s\u00e9zary syndrome: A retrospective analysis of the lymphoma working party of the European group for blood and marrow transplantation","volume":"28","author":"Duarte","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00277-018-3275-z","article-title":"Allogeneic hematopoietic stem cell transplantation in primary cutaneous T cell lymphoma","volume":"97","author":"Cudillo","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1093\/annonc\/mdx352","article-title":"Global patterns of care in advanced stage mycosis fungoides\/Sezary syndrome: A multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium","volume":"28","author":"Quaglino","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_14","unstructured":"(2020, January 06). NCCN Guidelines on Mycosis Fungoides\/S\u00e9zary Syndrome [Internet]. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/default_nojava.aspx#site."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3324\/haematol.2013.098145","article-title":"Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: A study from the french society of bone marrow transplantation and french study group on cutaneous lymphomas","volume":"99","author":"Bouaziz","year":"2014","journal-title":"Haematologica"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1182\/bloodadvances.2020001627","article-title":"Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma","volume":"4","author":"Weng","year":"2020","journal-title":"Blood Adv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1200\/JCO.2014.57.5597","article-title":"Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and s\u00e9zary syndrome: A European society for blood and marrow transplantation lymphoma working party extended analysis","volume":"32","author":"Duarte","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/bmt.2016.141","article-title":"Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation","volume":"51","author":"ElSawy","year":"2016","journal-title":"Bone Marrow Transpl."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Lansigan, F., Horwitz, S.M., Pinter-Brown, L.C., Carson, K.R., Shustov, A.R., Rosen, S.T., Pro, B., Hsi, E.D., Federico, M., and Gisselbrecht, C. (2020). Outcomes of patients with transformed mycosis fungoides: Analysis from a prospective multicenter US cohort study. Clin. Lymphoma Myeloma Leuk.","DOI":"10.1016\/j.clml.2020.05.001"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"214ra171","DOI":"10.1126\/scitranslmed.3007420","article-title":"Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma","volume":"5","author":"Weng","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"eaar5894","DOI":"10.1126\/scitranslmed.aar5894","article-title":"High-throughput sequencing of the T cell receptor \u03b2 gene identifies aggressive early-stage mycosis fungoides","volume":"10","author":"Elco","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/sj.bmt.1705968","article-title":"Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma","volume":"41","author":"Duarte","year":"2008","journal-title":"Bone Marrow Transpl."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2009.25.8301","article-title":"Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and s\u00e9zary syndrome","volume":"28","author":"Duvic","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/annonc\/mdv473","article-title":"Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: Updated results from a single institution","volume":"26","author":"Hosing","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/1078-0432.CCR-18-4147","article-title":"Radiotherapy eradicates malignant T cells and is associated with improved survival in early-stage mycosis fungoides","volume":"26","author":"Lowry","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): An international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3109\/10428194.2015.1044748","article-title":"Transformed mycosis fungoides: Bridging to allogeneic stem cell transplantation with brentuximab vedotin","volume":"57","author":"Schneeweiss","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1080\/10428194.2019.1605068","article-title":"Clinical and neurophysiological serial assessments of brentuximab vedotin-associated peripheral neuropathy","volume":"60","author":"Mariotto","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1080\/10428194.2019.1599112","article-title":"Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: A study on behalf of the SFGM-TC","volume":"60","author":"Garciaz","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/bjd.18806","article-title":"Effectiveness of brentuximab vedotin before and after allogeneic stem-cell transplantation in the management of transformed mycosis fungoides","volume":"182","author":"Battistella","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/bjd.18215","article-title":"Efficacy and safety of brentuximab vedotin plus bendamustine in advanced-stage primary cutaneous T-cell lymphomas","volume":"181","author":"Dumont","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1111\/bjd.17254","article-title":"Dramatic response to brentuximab vedotin in refractory nontransformed CD 30\u2014Mycosis fungoides allowing allogeneic stem cell transplant and long-term complete remission","volume":"180","author":"Mahevas","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_33","first-page":"233","article-title":"Challenges in the diagnosis of primary cutaneous CD 30 + anaplastic large-cell lymphoma","volume":"182","author":"Dobos","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): An international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/bjd.17320","article-title":"Association of autoimmunity and long-term complete remission in patients with S\u00e9zary syndrome treated with mogamulizumab","volume":"180","author":"Bonnet","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood-2015-10-672345","article-title":"Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD","volume":"127","author":"Alho","year":"2016","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/bmt.2015.315","article-title":"Pretransplant mogamulizumab against ATLL might increase the risk of acute GVHD and non-relapse mortality","volume":"51","author":"Inoue","year":"2015","journal-title":"Bone Marrow Transpl."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jamadermatol.2018.0884","article-title":"Potential association of anti-CCR4 antibody mogamulizumab and graft-vs-host disease in patients with mycosis fungoides and s\u00e9zary syndrome","volume":"154","author":"Dai","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.bbmt.2009.04.017","article-title":"A Meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and s\u00e9zary syndrome","volume":"15","author":"Wu","year":"2009","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/sj.bmt.1705741","article-title":"Graft versus lymphoma effect after early relapse following reduced-intensity sibling allogeneic stem cell transplantation for relapsed cytotoxic variant of mycosis fungoides","volume":"40","author":"Gabriel","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jdcr.2017.02.004","article-title":"Complete durable remission of a fulminant primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma after autologous and allogeneic hematopoietic stem cell transplantation","volume":"3","author":"Plachouri","year":"2017","journal-title":"JAAD Case Reports"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/bmt.2014.161","article-title":"Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome","volume":"49","author":"Lechowicz","year":"2014","journal-title":"Bone Marrow Transpl."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Gagelmann, N., Bacigalupo, A., Rambaldi, A., Hoelzer, D., Halter, J., Sanz, J., Bonifazi, F., Meijer, E., It\u00e4l\u00e4-Remes, M., and Markov\u00e1, M. (2019). Haploidentical stem cell transplantation with posttransplant cyclophosphamide therapy vs other donor transplantations in adults with hematologic cancers: A systematic review and meta-analysis. JAMA Oncol.","DOI":"10.1001\/jamaoncol.2019.3541"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s12185-013-1410-0","article-title":"Reduced-intensity conditioning followed by cord blood transplantation in a patient with refractory folliculotropic mycosis fungoides","volume":"98","author":"Nakaike","year":"2013","journal-title":"Int. J. Hematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/j.1346-8138.2010.00985.x","article-title":"Two cases of mycosis fungoides treated by reduced-intensity cord blood transplantation: Two cases of mycosis fungoides","volume":"37","author":"Tsuji","year":"2010","journal-title":"J. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/S\u00e9zary syndrome","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.11127","article-title":"Low-dose intermittent alemtuzumab in the treatment of S\u00e9zary syndrome: Clinical and immunologic findings in 14 patients","volume":"92","author":"Bernengo","year":"2007","journal-title":"Haematologica"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/bjd.12690","article-title":"Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas","volume":"170","author":"Guitera","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"117ra7","DOI":"10.1126\/scitranslmed.3003008","article-title":"Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients","volume":"4","author":"Clark","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"7497","DOI":"10.4081\/hr.2018.7497","article-title":"Long-term complete remission of early hematological relapse after discontinuation of immunosuppressants following allogeneic transplantation for Sezary syndrome","volume":"10","author":"Hosoi","year":"2018","journal-title":"Hematol. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/bmt.2014.227","article-title":"A multicentre UK study of GVHD following DLI: Rates of GVHD are high but mortality from GVHD is infrequent","volume":"50","author":"Scarisbrick","year":"2014","journal-title":"Bone Marrow Transpl."},{"key":"ref_52","first-page":"39","article-title":"Allogeneic stem cell transplantation in patients with aggressive primary cutaneous T-cell lymphoma\u2014A case series of the ADF working group \u201ccutaneous lymphomas\u201d","volume":"12","author":"Moritz","year":"2014","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1182\/blood-2018-99-119566","article-title":"Donor lymphocyte infusion for primary cutaneous T cell lymphomas: A study from the francophone society of bone marrow transplantation and cellular therapy (SFGM-TC) and the french study group on cutaneous lymphomas (GFLEC)","volume":"132","author":"Faiz","year":"2018","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.trim.2011.06.008","article-title":"Donor lymphocyte infusions combined with systemic PUVA\/bexarotene as an effective bimodal immunologic approach in a patient with relapsed cutaneous T cell lymphoma after allogeneic stem cell transplantation","volume":"25","author":"Schlaak","year":"2011","journal-title":"Transpl. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jid.2018.10.025","article-title":"Who needs a skin exam? Skin cancers in allogeneic hematopoietic stem cell transplant recipients in the contemporary era","volume":"139","author":"Bouaziz","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(13)70512-6","article-title":"Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: A phase 1\/2 trial","volume":"15","author":"Choi","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/hon.2162","article-title":"Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning for mycosis fungoides and Sezary syndrome","volume":"34","author":"Shiratori","year":"2016","journal-title":"Hematol. Oncol."},{"key":"ref_58","first-page":"816","article-title":"Allogeneic haematopoietic stem cell transplantation for patients with cutaneous T-cell lymphoma","volume":"96","author":"Niittyvuopio","year":"2014","journal-title":"Acta Derm. Venereol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1046\/j.1365-2559.2003.01591.x","article-title":"Differential diagnosis of skin lesions after allogeneic haematopoietic stem cell transplantation","volume":"42","author":"Dijk","year":"2003","journal-title":"Histopathology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/bjh.14479","article-title":"Pathology findings in patients with cutaneous T-cell lymphomas treated with allogeneic haematopoietic stem cell transplantation","volume":"180","author":"Menter","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2018-02-811174","article-title":"Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: Taming a necessary evil","volume":"132","author":"Herbaux","year":"2018","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in relapsed and refractory mycosis fungoides and s\u00e9zary syndrome: A multicenter phase II study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/bmt.2017.69","article-title":"Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma","volume":"52","author":"Massoud","year":"2017","journal-title":"Bone Marrow Transpl."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3389\/fonc.2019.00259","article-title":"CAR-based approaches to cutaneous T-cell lymphoma","volume":"9","author":"Frigault","year":"2019","journal-title":"Front. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/10\/2856\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:16:18Z","timestamp":1760177778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/10\/2856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,3]]},"references-count":64,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["cancers12102856"],"URL":"https:\/\/doi.org\/10.3390\/cancers12102856","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,3]]}}}